跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT01266993
NCT01266993已完成3 期

Persistence of Antibodies After Vaccination With a Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children and Safety and Immunogenicity of a Booster Dose at 68 Months Post-primary Vaccination

GlaxoSmithKline25 个研究点 分布在 2 个国家目标入组 271 人开始时间: 2011年1月3日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
271
试验地点
25
主要终点
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:8, at Month 56.
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of the study is to evaluate the persistence of the immune response of GSK134612 vaccine up to 68 months after vaccination in the primary vaccination study (NCT number = NCT00674583) of 2 to 10 year old subjects. This study will also evaluate the safety and immunogenicity of a booster dose of GSK134612 vaccine subjects who were primed in the primary vaccination study with either GSK134612 vaccine or Menjugate®.

This protocol posting deals with objectives & outcome measures of the persistence and booster epochs. The objectives & outcome measures of the primary epoch are presented in a separate protocol posting (NCT number = NCT00674583)

详细描述

Subjects were previously vaccinated at 2 to 10 years of age with GSK134612 or with Menjugate®. The persistence phase starts 32 months after the primary vaccination and blood samples will be taken at 32, 44, 56 and 68 months after primary vaccination. All subjects will receive a booster dose of GSK134612 at 68 months after primary vaccination and a blood sample will be taken 1 month after administration of the booster dose.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
4 Years 至 16 Years（Child）
性别
All
接受健康志愿者
是

入选标准

  • •Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol should be enrolled in the study.
  • •A male or female who was primed with MenACWY-TT or Menjugate in the primary vaccination study (NCT number = NCT00674583).
  • •Written informed consent obtained from the parent(s)/Legally Acceptable Representatives(s) of the subject and written informed assent obtained from the subject (at investigator discretion).
  • •Healthy subjects as established by medical history and clinical examination before entering into the study.
  • •All subjects must meet the additional following criteria prior to receiving the booster vaccination:
  • •Subjects who had a blood sample taken at Visit 4 during the persistence epoch of the current study.
  • •Female subjects of non-childbearing potential may be enrolled in the study.
  • •Female subjects of childbearing potential may be enrolled in the study, if the subject:
  • •has practiced adequate contraception for 30 days prior to vaccination, and
  • •has a negative pregnancy test on the day of vaccination, and
  • •has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

排除标准

  • •Child in care.
  • •Use of any investigational or non-registered product within 30 days preceding the first persistence blood sample or planned use within 30 days preceding a blood sample during the study period.
  • •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, prednisone <10 mg/day, or equivalent, inhaled and topical steroids are allowed).
  • •Concurrently participating in another clinical study or planned participation in another clinical study, in which the subject has been or will be exposed to an investigational or a non-investigational product within 30 days of a blood sample.
  • •History of meningococcal disease.
  • •Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine since the previous vaccination in the primary vaccination study (NCT number = NCT00674583).
  • •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection, based on medical history and physical examination.
  • •Serious chronic illness.
  • •Administration of immunoglobulins and/or blood products within the 3 months preceding the subject's first visit.
  • •Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.
  • •Subjects in contact with somebody suffering from an invasive infection with meningococcal serogroups A, C, Y or W-
  • •Subjects living in a geographic area where local outbreak with meningococcal serogroup C has occurred.
  • •Exclusion criteria for booster vaccination to be checked at Visit 4 (Month 68)
  • •Child in care.
  • •Use of any investigational or non-registered product within 30 days preceding the booster vaccination or planned use during the study period.
  • •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination. (For corticosteroids, prednisone <10 mg/day, or equivalent, inhaled and topical steroids are allowed).
  • •Vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, B, C, W-135, and/or Y since the previous vaccination in the primary vaccination study (NCT number = NCT00674583).
  • •History of meningococcal disease.
  • •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection, based on medical history and physical examination.
  • •Administration of immunoglobulins and/or any blood products within the three months preceding the booster vaccination or planned administration during the study period.
  • •Concurrently participating in another clinical study or planned participation in another clinical study, at any time during the study period, (from the time of the booster until the end of the study) in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • •Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.
  • •Hypersensitivity to latex.
  • •Planned administration/ administration of a vaccine not foreseen by the study protocol within the last 30 days of the dose of vaccine(s) with the exception of a licensed inactivated influenza vaccine.
  • •Previous vaccination with tetanus toxoids within the last 30 days.
  • •A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
  • •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • •Serious chronic illness.
  • •History of any neurological disorders or seizures (although subjects with a prior history of a single episode of benign febrile seizures may be allowed to participate in the study).
  • •Acute disease and/or fever at the time of vaccination.
  • •History of chronic alcohol consumption and/or drug abuse.
  • •History of hypotonic-hyporesponsive episodes (HHEs) following vaccination.
  • •Subjects in contact with somebody suffering from an invasive infection with meningococcal serogroups A, C, Y or W-
  • •Subjects living in a geographic area where local outbreak with meningococcal serogroup C has occurred.
  • •Pregnant or lactating female.
  • •Female of child-bearing potential planning to become pregnant or planning to discontinue contraceptive precautions.

结局指标

主要结局

Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:8, at Month 56.

时间窗: At Month 56, post-primary vaccination

The pre-defined cut-off value of the assay for the rSBA titers was greater than or equal to (≥) 1:8. These analyses have been performed by the Health Protection Agency (HPA) laboratory.

Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:8, at Month 44.

时间窗: At Month 44, post-primary vaccination

The pre-defined cut-off value of the assay for the rSBA titers was greater than or equal to (≥) 1:8. These analyses have been performed by the Health Protection Agency (HPA) laboratory.

Number of Subjects With Serum Bactericidal Assay, Using Baby Rabbit Complement, Against Neisseria Meningitides Serogroup A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Antibody Titers Was Greater Than or Equal to (≥) 1:8, at Month 32.

时间窗: At Month 32, post-primary vaccination

The pre-defined cut-off value of the assay for the rSBA titers was greater than or equal to (≥) 1:8. These analyses have been performed by the Health Protection Agency (HPA) laboratory.

Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:8, at Month 68.

时间窗: At Month 68, post-primary vaccination

The pre-defined cut-off value of the assay for the rSBA titers was greater than or equal to (≥) 1:8. These analyses have been performed by the Health Protection Agency (HPA) laboratory.

次要结局

  • Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:128, at Month 56.(At Month 56, post-primary vaccination)
  • Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:128, at Month 32.(At Month 32, post-primary vaccination)
  • Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:128, at Month 44.(At Month 44, post-primary vaccination)
  • Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:128, at Month 68.(At Month 68, post-primary vaccination)
  • Antibody Titers for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY, at Month 32.(At Month 32, post-primary vaccination)
  • Antibody Titers for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY, at Month 44.(At Month 44, post-primary vaccination)
  • Antibody Titers for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY, at Month 56.(At Month 56, post-primary vaccination)
  • Antibody Titers for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY, at Month 68.(At Month 68, post-primary vaccination)
  • Number of Subjects With Serum Bactericidal Assay, Using Human Complement, Against N. Meningitides Serogroup A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY) Antibody Titers ≥ 1:4 and ≥ 1:8, at Month 32.(At Month 32, post-primary vaccination)
  • Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers ≥ 1:4 and ≥ 1:8, at Month 44.(At Month 44, post-primary vaccination)
  • Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers ≥ 1:4 and ≥ 1:8, at Month 56.(At Month 56, post-primary vaccination)
  • Antibody Titers for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY, at Month 44.(At Month 44, post-primary vaccination)
  • Antibody Titers for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY, at Month 68.(At Month 68, post-primary vaccination)
  • Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ 1:128 and 1:8.(At Month 69, one month post-booster vaccination)
  • Antibody Titers for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY(At Month 69, one month post-booster vaccination)
  • Number of Subjects With a Vaccine Response to rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibodies(At Month 69, one month post-booster vaccination)
  • Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers ≥ 1:4 and ≥ 1:8, at Month 68.(At Month 68, post-primary vaccination)
  • Antibody Titers for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY, at Month 32.(At Month 32, post-primary vaccination)
  • Antibody Titers for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY, at Month 56.(At Month 56, post-primary vaccination)
  • Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers ≥ 1:4 and 1:8.(At Month 69, one month post-booster vaccination)
  • Antibody Titers for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY(At Month 69, one month post-booster vaccination)
  • Number of Subjects With a Vaccine Response to hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibodies(At Month 69, one month post-booster vaccination)
  • Number of Subjects With Any and Grade 3 Solicited Local Symptoms(During the 4-day (Days 0-3) period following the booster vaccination)
  • Number of Subjects With Any, Grade 3 and Solicited General Symptoms(During the 4-day (Days 0-3) period following the booster vaccination)
  • Number of Subjects With Any Unsolicited Adverse Events (AEs)(During the 31-day (Days 0-30) period following the booster vaccination)
  • Number of Subjects With Serious Adverse Events (SAEs)(During the 31-day (Days 0-30) period following the booster vaccination)
  • Number of Subjects With Any New Onset of Chronic Illnesses (NOCIs)(During the 31-day (Days 0-30) period following the booster vaccination)
  • Number of Subjects With Serious Adverse Events SAEs(Up to Month 32, 44, 56 and 68)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (25)

Loading locations...

相似试验

撤回
3 期
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary StudyInfections, Papillomavirus
NCT02100618GlaxoSmithKline
已完成
3 期
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 StudyCervical Intraepithelial Neoplasia
NCT03355820GlaxoSmithKline228
已完成
2 期
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/AdultsInfections, Meningococcal
NCT00715910GlaxoSmithKline818
已完成
3 期
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsPoliomyelitisHepatitis BDiphtheriaTetanusPertussis
NCT00303316Sanofi458
已完成
3 期
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young AdultsAcellular PertussisDiphtheriaTetanus
NCT01738477GlaxoSmithKline165